Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-01-04 @ 1:44 PM
Study NCT ID:
NCT02562066
Status:
COMPLETED
Last Update Posted:
2021-04-02
First Post:
2015-09-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Sponsor:
Catalyst Pharmaceuticals, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CMS-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None